Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
36 studies found for:    " September 15, 2010":" October 15, 2010"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
" September 15, 2010":" October 15, 2010"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Active, not recruiting Longitudinal Study of Dental Implant Therapy in HIV- Positive Patients
Condition: HIV Positive Patient Receive Implant Supported Restoration
Intervention:
2 Terminated Dose-finding Study of GSK2248761 in Antiretroviral Therapy-Naive Subjects (SIGNET)
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK2248761 100 mg once daily;   Drug: GSK2248761 200 mg once daily;   Drug: Efavirenz 600 mg once daily
3 Recruiting Chinese Network of Pediatric Antiretroviral Therapy
Condition: Acquired Immunodeficiency Syndrome
Intervention:
4 Active, not recruiting A Study to Assess the Efficacy of Raltegravir, Administered in Combination With Other Antiretroviral Drugs as Treatment for Adults and Older Adults Infected With the Human Immunodeficiency Virus 1 (HIV-1)(MK-0518-145) (Wirksamkeit Von Isentress® Unter Praxisbedingungen)
Condition: HIV-1 Infection
Intervention: Drug: Raltegravir
5 Recruiting Umbilical Cord Mesenchymal Stem Cells for Immune Reconstitution in HIV-infected Patients
Conditions: Human Immunodeficiency Virus;   Disorder of Immune Reconstitution
Interventions: Drug: high dose of MSC;   Drug: low dose of MSC treatment
6 Unknown  R5 Integrase Study in HIV-1 Naive Patients
Condition: HIV Infections
Intervention: Drug: Raltegravir and Maraviroc in combination
7 Unknown  The Effect of HIV Tat Protein on HCV Replication in an In-vitro Model System
Conditions: Human Immunodeficiency Virus (HIV);   Hepatitis C, Chronic
Intervention:
8 Active, not recruiting
Has Results
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
Condition: Infection, Human Immunodeficiency Virus I
Interventions: Drug: GSK1349572 (dolutegravir);   Drug: raltegravir;   Other: GSK1349572 Placebo;   Other: ABC/3TC;   Other: TDF/FTC;   Other: raltegravir Placebo
9 Completed HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir
Conditions: Chronic HIV Infection;   HCV Coinfection
Intervention: Drug: Fosamprenavir
10 Recruiting Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males
Conditions: Anal Cancer;   Nonneoplastic Condition;   Penile Cancer;   Precancerous Condition
Interventions: Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine;   Other: laboratory biomarker analysis
11 Active, not recruiting Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)
Condition: HIV
Intervention: Drug: Tenofovir/emtricitabine and raltegravir
12 Completed A Study to Assess the Relative Bioavailability of Tablet Formulations of GSK2248761 in Healthy Adult Subjects. SGN114435
Conditions: Infections, Human Immunodeficiency Virus and Herpesviridae;   Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK2248761 WBM Capsule;   Drug: GSK2248761 WBM Tablet Formulation 1;   Drug: GSK2248761 WBM Tablet Formulation 2;   Drug: GSK2248761 WBM Tablet Formulation 3;   Drug: GSK2248761 WBM Tablet
13 Completed Identifying Undiagnosed Asymptomatic HIV Infection in Hispanic/Latino Adolescents and Young Adults
Condition: HIV
Intervention: Behavioral: Effectiveness of different strategies in HIV testing and linkage to care
14 Completed
Has Results
Drug Use Investigation On Zithromac (Azithromycin) In HIV Patients
Condition: HIV Infection
Intervention: Drug: Azithromycin
15 Completed Safety and Immunogenicity Study of Ad26-ENVA and Ad35-ENV HIV Vaccines in Healthy HIV-uninfected Adults
Condition: HIV Infections
Interventions: Biological: Ad35-ENV vaccine;   Biological: Ad26.ENVA.01 vaccine;   Biological: Placebo Control
16 Active, not recruiting Use of Rosuvastatin in HIV-Infected Subjects to Modulate Cardiovascular Risks
Conditions: HIV Infections;   Heart Disease
Interventions: Drug: Rosuvastatin 10 mg. daily for 96 weeks;   Drug: Placebo
17 Completed Non-virologic Methods to Diagnose Treatment Eligibility in HIV-exposed Infants
Condition: HIV Infections
Intervention:
18 Completed GSK1349572 Hepatic Impairment Study
Conditions: Healthy Subjects;   Hepatic Impairment;   Infection, Human Immunodeficiency Virus
Intervention: Drug: GSK1349572
19 Recruiting ZIAGEN® Post-marketing Surveillance
Condition: Infection, Human Immunodeficiency Virus I
Intervention: Drug: ZIAGEN®
20 Completed A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects
Condition: Infections, Human Immunodeficiency Virus and Tuberculosis
Interventions: Drug: GSK1349572;   Drug: Placebo;   Drug: Iohexol Injection;   Drug: Para-aminohippurate infusion

   Previous Page Studies Shown (1-20) Next Page (21-36) Show next page of results    Last Page
Indicates status has not been verified in more than two years